Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Check-CapFRA:7CC -5.77%35 EV-to-EBITDA is 2.73 as of Aug. 16, 2026. GuruFocus rates FRA:7CC with a GF Score™ of 35/100. The stock has 2 warning signs investors should review. Among 119 Medical Diagnostics & Research companies, Check-Cap ranks better than 94.12% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Check-Cap's enterprise value is €10.03 Mil.
Check-Cap's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €3.68 Mil. Therefore, Check-Cap's EV-to-EBITDA for today is 2.73.
The historical rank and industry rank for Check-Cap's EV-to-EBITDA or its related term are showing as below:
FRA:7CC'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 0 Med: 0 Max: 2.68
Current: 2.68
During the past 13 years, the highest EV-to-EBITDA of Check-Cap was 2.68. The lowest was 0.00. And the median was 0.00.
FRA:7CC's EV-to-EBITDA is ranked better than 94.12% of 119
companies
in the Medical Diagnostics & Research industry
Industry Median: 16.19
vs FRA:7CC: 2.68
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Check-Cap's share price for today is €7.35.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Check-Cap's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €4.026.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Check-Cap's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:7CC vs XWEL, NDRA, BIAF: EV-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Check-Cap's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Check-Cap EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Check-Cap's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Check-Cap's EV-to-EBITDA falls into.
Check-Cap's current Enterprise Value is €10.03 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Check-Cap's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €3.68 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Check-Cap (FRA:7CC) has a EV-to-EBITDA of 2.73 as of Aug. 16, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Check-Cap. According to the industry distribution chart, Check-Cap ranks #7 out of 119 companies in the Medical Diagnostics & Research industry, placing it in the top 5.9%.
Is Check-Cap's EV-to-EBITDA too high?
Check-Cap's current EV-to-EBITDA is 2.73. The Medical Diagnostics & Research industry median EV-to-EBITDA is 16.19. Check-Cap's value of 2.73 is 83.1% below this industry median. Based on the distribution chart, Check-Cap ranks #7 out of 119 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Check-Cap has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Check-Cap's EV-to-EBITDA compare to XWEL and NDRA?
According to the Medical Diagnostics & Research industry distribution chart, Check-Cap ranks #7 out of 119 companies for EV-to-EBITDA. This places Check-Cap in the top 6% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 16.19. Check-Cap's value of 2.73 is 83.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 16.19, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Check-Cap's current EV-to-EBITDA of 2.73 is 83.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Check-Cap. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 16.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Check-Cap's current EV-to-EBITDA is 2.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Check-Cap stock overvalued right now?
Check-Cap (FRA:7CC) has a current EV-to-EBITDA of 2.73. The current EV-to-EBITDA is 2.73 and 83.1% below the Medical Diagnostics & Research industry median of 16.19. Check-Cap's overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Check-Cap (FRA:7CC), the current EV-to-EBITDA is 2.73 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but plans to market products in the United States, Europe, Israel and Japan.
35GF Score
Get the complete analysis for FRA:7CC
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7CC has been successfully added to your 
